



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/628,984

07/28/2003

Guohua Chen

ARC 3119 R1

7536

Edgar R Cataxinos
TraskBritt PC
P O Box 2550
Salt Lake City, UT 84110

7590

01/05/2011

EXAMINER

ARNOLD, ERNST V

ART UNIT

PAPER NUMBER

1613

MAIL DATE

DELIVERY MODE

01/05/2011

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/628,984	Applicant(s) CHEN ET AL.	
	Examiner ERNST V. ARNOLD	Art Unit 1613	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 9/17/10.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 2,3,6,9-19,21-34,37-47 and 49-84 is/are pending in the application.
- 4a) Of the above claim(s) 21-27 and 49-83 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 2,3,6,9-19,28-34,37-47 and 84 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/17/10 has been entered.

Claims 1, 4, 5, 7, 8, 20, 35, 36 and 48 have been cancelled. Claims 21-27 and 49-83 are withdrawn. Claims 2, 3, 6, 9-19, 28-34, 37-47 and 84 are under examination.

Withdrawn rejections:

Applicant's amendments and arguments filed 9/17/10 are acknowledged and have been fully considered. Any rejection and/or objection not specifically addressed below is herein withdrawn. Claims 2, 3, 6, 9-19, 28-35, 37-47 and 84 were rejected under 35 U.S.C. 103(a) as being unpatentable over Brodbeck et al. (US 6,331,311) in view of Brodbeck et al. (6,130,200), and Penco et al. (Polymer International 1998, 46, 203-216) and Ravivarapu et al. (European Journal of Pharmaceutics and Biopharmaceutics 50 (2000)263-270). This rejection is withdrawn in favor of the rejection to follow.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

The terms "low", "medium", and "high" in claims 2, 3, 28, 29-31 and 84 are relative terms which renders the claim indefinite. The terms "low", "medium", and "high" are not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. In claim 33, the "low" molecular weight polymer can be 'about 10000' which overlaps with the "medium" molecular weight polymer which has the same 'about 10000' MW. Similarly, the "medium" and "high" molecular weight polymers can both have a MW above 30000 because 'about 30000' reads on values greater than 30000. Thus the scope of what is meant by low, medium and high is blended and not distinct because something that is low MW can also be medium MW and vice versa. Thus it is unclear what is meant by the claims and the ordinary artisan would not know when a low or medium or high MW polymer was being used. Claims 6, 9-19, 32-35 and 37-47 are rejected as indefinite because they are dependent on an indefinite base claim.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 33 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as

Art Unit: 1613

the invention. In claim 33, the “low” molecular weight polymer can be ‘about 10000’ which overlaps with the “medium” molecular weight polymer which has the same ‘about 10000’ MW. Similarly, the “medium” and “high” molecular weight polymers can both have a MW above 30000 because ‘about 30000’ reads on values greater than 30000. Thus the scope of what is meant by low, medium and high is blended and not clear because, for example, something that is low MW can also be medium MW and vice versa. Thus it is unclear what is meant by the claims and the ordinary artisan would not know when a low or medium or high MW polymer was being used.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 2, 3, 6, 9-19, 28-34, 37-47 and 84 are rejected under 35 U.S.C. 103(a) as being unpatentable over Brodbeck et al. (US 6,331,311) in view of Brodbeck et al. (6,130,200), and Penco et al. (Polymer International 1998, 46, 203-216) and Ravivarapu et al. (European Journal of Pharmaceutics and Biopharmaceutics 50 (2000)263-270) and Bodmeier et al. (International Journal of Pharmaceutics 1989, 51, 1-8) and Le Corre et al. (International Journal of Pharmaceutics 1994, 107, 41-49).

Applicant claims an injectable gel composition comprising a plurality of bioerodible, biocompatible polymers, solvent and a beneficial agent.

Determination of the scope and content of the prior art

(MPEP 2141.01)

Art Unit: 1613

Brodbeck et al. teach an injectable depot gel composition comprising a biocompatible polymer such as lactic acid based polymers with a number average molecular weight of from 1,000 to 120,000, an organic solvent, emulsifying agent and a beneficial agent dispersed in the gel (Abstract and claims 1-3 and 5). Claims 1-3 are reproduced below for Applicant's benefit (examiner added emphasis):

1. An injectable depot gel composition comprising:
a continuous, viscous gel phase comprising
a biocompatible polymer and
5 an organic solvent that dissolves the biocompatible polymer and forms a viscous gel;
a beneficial agent; and a separate, droplet phase dispersed in the viscous gel phase comprising
an emulsifying agent, whereby the depot gel composition is thixotropic.
2. The injectable gel depot composition of claim 1 wherein the biocompatible polymer is selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamines, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, poly(malic acid), poly(amino acids), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, and
0 copolymers, terpolymers and mixtures thereof.
3. The injectable depot gel composition of claim 1 wherein the biocompatible polymer is a lactic acid-based polymer.

Claim 4 recites the lactic acid based polymer has a monomer ratio of lactic acid to glycolic acid in the range of 100:0 to about 15:85 (claim 4). Clearly, Brodbeck et al. contemplate the use of

Art Unit: 1613

biodegradable and biocompatible lactic acid based polymers. Furthermore, Brodbeck et al. teach mixtures of the lactic acid based polymers in the molecular weight range of from 1000 to 120,000 (claim 5). Thus, one interpretation of the claims is that Brodbeck et al. teach mixtures of lactic acid based polymers of a wide molecular weight range. This would include low, medium and high molecular weight polymers in the range of claim 5. Brodbeck et al. teach the solvent is present from 20 to 95 % by weight of the combined amounts of polymer and solvent (Claim 10). Therefore the polymer must be from 5 to 80 % by weight of the composition. '311 teaches benzyl benzoate, an aromatic ester, as a solvent (column 5, lines 8-15) and alcohols, polyols, esters, carboxylic acids, ketones, aldehydes and mixtures thereof as emulsifying agents (claims 19). Brodbeck et al. teach prolonged release of the beneficial agent up to 90 days and modifying the release by adjusting the amounts of components for any given polymer and any given solvent (column 7, line 35 bridging column 8, line 53). Brodbeck et al. teach a kit for the injectable depot composition with the components (a) a biocompatible polymer and organic solvent; (b) emulsifying agent and (c) the beneficial agent (claim 27). The beneficial agent is thus separated from the solvent and mixed before use (column 8, lines 53-61). (Note: components (d)-(g) are optional in instant claim 84).

Brodbeck et al. '200 teach a gel composition for implantation of a beneficial agent to a subject comprising a biocompatible polymer, a biocompatible solvent with low water miscibility that forms a gel with the polymer and a beneficial agent (Abstract). Brodbeck et al. '200 teach poly(lactide-co-glycolide) copolymer, benzyl benzoate and a beneficial agent (Claims 1-3) wherein the copolymer has a number average molecular weight of from 1,000 to 120,000 (claim 15). A component solvent can be added such as diethyl phthalate (claim 17). Brodbeck et al.

Art Unit: 1613

'200 teach that useful solvents are less than 7% water soluble by weight (column 12, lines 12-65). Brodbeck et al. '200 teach the use of RESOMER® RG502 AND RESOMER® RG503 for use in the invention (column 24, line 46 bridging column 25, line 5). Brodbeck et al. '200 teach adding pore formers such as salts and solvents which are also osmotic agents and emulsifying agents such as glycerol and water which are also solubility modulators to the gel (claims 5, 6, 9, 10, 11-13).

Penco et al. teach benzyl alcohol as a known solvent for PLGA (page 204-205, 2. synthesis).

Bodmeier et al. teach preparation of microspheres with blends of high molecular weight poly(DL-lactide) MW = 120,000 and low molecular weight poly(DL-lactide) MW = 2000 with active agents such as salicylic acid and quinidine in ratios of high MW to low MW of 100/0, 90/10, 80/20, 70/30, 60/40, 50/50 and 40/60 (Abstract and Materials and Methods).

Biodegradable drug delivery systems were prepared with durations of action between several hours to months by varying the amount of low molecular weight poly(DL-lactide) (Abstract and Figures 1-6). Thus the concept of an drug delivery 'depot' with high and low molecular weight poly(DL-lactide) is already known in the art.

Le Corre et al. teach blends of polylactic acid R104 of 2000 MW and polylactic acid R202 of 9000 MW for drug delivery microspheres in blends of PLA R104 to PLA R202 of: 100/0, 75/25, 50/50, 25/75 and 0/100 (Abstract; Methods and Materials; Figure 2 and Table 1). Blending of the polymers allowed for the regulation of drug release (page 47, right column and Table 1).

Art Unit: 1613

Ravivarapu et al. teach, in the Abstract, the concept combining PLGA polymers that varied in their molecular weights in various ratios yielded microspheres with varied drug release profiles commensurate with the hydration tendencies of the polymers. Increasing the component of lower molecular weight 50:50 hydrophilic PLGA polymer, 8.6 kDa increased the initial drug release. A similar microsphere formulation prepared instead with blending microspheres from individual polymers showed a similar increase. In an animal model, microspheres obtained from polymer or microsphere blends attained a faster onset of testosterone suppression as compared to microspheres from higher molecular weight 50:50 hydrophilic PLGA polymer, 28.3 kDa, alone. Ravivarapu et al. explain on page 268, right column (examiner added emphasis):

and during the 14–49 day period. PLGA polymers degrade hydrolytically giving rise to an acidic microenvironment in the particle structure [21] which enhances polymer degradation and mass loss. An acidic microenvironment is attained faster in the case of the 8.6 kDa PLGA as this polymer hydrates faster owing to its higher number of carboxylic acid endgroups. Additionally, microspheres from the lower MW polymer had a more porous internal structure which would also facilitate hydration. Thus, microspheres that contain 8.6 kDa PLGA as a combination in their structure are expected to degrade and release drug faster as compared to microspheres that are physically blended, as the hydration of the 8.6 kDa polymer will also hydrate the closely associated 28.3 kDa polymer. This may explain the higher drug release seen with polymer combination formulations at later time points. However, as the noted difference

These studies illustrated the concept of blending polymers or microspheres of varied characteristics in achieving modified drug release. It is then understood by one of ordinary skill in the art that low MW PLGA degrades faster and results and faster drug release while higher MW PLGA degrades more slowly thus manifesting a slower drug release and mixtures of the different MW polymers produces a blended release profile.

Ascertainment of the difference between the prior art and the claims

(MPEP 2141.02)

1. The difference between the instant invention and Brodbeck et al. '311 is that Brodbeck et al '311 does not expressly teach mixtures of high, medium and low molecular weight lactic acid based polymers in the injectable drug depot wherein the low molecular weight polymer is about 20 to about 90 wt%. This deficiency is cured by the teachings of Bodmeier et al., Le Corre et al., Brodbeck et al '200 and Ravivarapu et al..

2. The difference between the instant invention and Brodbeck et al '311 is that Brodbeck et al '311 does not expressly teach benzyl alcohol as a solvent. This deficiency in Brodbeck et al '311 is cured by the teachings of Penco et al.

3. The difference between the instant invention and Brodbeck et al '311 is that Brodbeck et al '311 does not expressly teach adding pore formers, solubility modulators and osmotic agents maintained separately from the solvent until time of administration of the beneficial agent to the subject to the kit. This deficiency is cured by the teachings of Brodbeck et al '200.

Finding of prima facie obviousness

Rational and Motivation (MPEP 2142-2143)

1. It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to use a mixture of high, medium and low biocompatible lactic acid based polymers as taught by Bodmeier et al., Le Corre et al., and Brodbeck et al '311 and use for example the lactic acid based polymers RESOMER® RG502 AND RESOMER® RG503, as suggested by Brodbeck et al '200, or other polylactic acid polymers and in various molecular weights, as taught by Bodmeier et al., Le Corre et al., and Ravivarapu et al., in the gel depot of Brodbeck et al '311 and produce the instant invention.

One of ordinary skill in the art would have been motivated to do this because Brodbeck et al. '311 broadly claim all polylactides and the art of Bodmeier et al. and Le Corre et al. teach which polylactides are useful for making 'depots' with various molecular weight mixtures of 'high', 'medium' and 'low' MW poly(DL-lactide) for modifying drug delivery rates. Furthermore, Brodbeck et al. '311 teaches one of ordinary skill in the art mixtures of polylactides and copolymers thereof and teaches a wide range of molecular weights that encompass the instantly claimed high, medium and low molecular weight ranges that can be used to make the injectable drug depot gel composition. Ravivarapu et al., Le Corre et al. and Bodmeier et al. teach the benefits of combining polymers/microspheres of different molecular weights to achieve different active release profiles. It is then merely routine optimization and judicious selection of known components in the art, for example RESOMER® RG502 AND RESOMER® RG503, for use in the composition especially when Brodbeck et al '200 teaches use of these materials for the same purpose. With respect to the limitation of systemic delivery of the beneficial agent over a duration of one year or local delivery of the beneficial agent over a duration of up to one year, that is merely routine optimization, as taught by Brodbeck et al '311, of the components to arrive at that desired release profile.

Regarding the relative amount of low molecular weight polymer of about 20 to about 90 wt% in the matrix recited in Applicants' dependent claims; this amount is taught by Bodmeier et al. and Le Corre et al.

2. It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to use benzyl alcohol, as taught by Penco et al., as the solvent in the composition of Brodbeck et al '311 and produce the instant invention.

One of ordinary skill in the art would have been motivated to do this because benzyl alcohol is a known solvent for PLGA polymers as taught by Penco et al. Benzyl alcohol intrinsically has the properties of water miscibility instantly claimed in the absence of evidence to the contrary (see instant claims 12-15 and 40-43).

3. It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to use pore formers, solubility modulators and osmotic agents maintained separately from the solvent until time of administration of the beneficial agent to the subject to the kit in the kit of Brodbeck et al '311, as suggested by Brodbeck et al. '200, and produce the instant invention.

One of ordinary skill in the art would have been motivated to do this because: 1) all these ingredients are optional and thus not required; but if required then: "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980); and 2) keeping the osmotic agent separate from the solvent is merely a design choice by the artisan since they will be combined at time of administration and which time is not disclosed.

A reference is good not only for what it teaches by direct anticipation but also for what one of ordinary skill in the art might reasonably infer from the teachings. (In re Opprecht 12 USPQ 2d 1235, 1236 (Fed Cir. 1989); In re Bode 193 USPQ 12 (CCPA) 1976).

In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a).

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Response to arguments:

Applicant's arguments are moot in view of the new ground of rejection.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERNST V. ARNOLD whose telephone number is (571)272-8509. The examiner can normally be reached on M-F 7:15-4:45.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Kwon can be reached on 571-272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1613

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Ernst V Arnold/
Primary Examiner, Art Unit 1613